Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb
Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb
复制标题
DOI：
10.1038/srep03365
复制
发表时间：
2013-11-28
影响因子：
4.6
通讯作者：
Kobinger, Gary P.
中科院分区：
文献类型：
--
作者：
Qiu, Xiangguo;Audet, Jonathan;Kobinger, Gary P.
埃博拉病毒（EBOV）是最致命的丝状病毒之一，人类死亡率高达90%。此前，我们证明了在暴露后24小时或48小时分别给予3种EBOV-GP特异性单克隆抗体（ZMAb）的组合，感染EBOV的食蟹猴的存活率分别为100%和50%。存活者表现出EBOV-GP特异性体液和细胞介导的免疫应答。为了评价在ZMAb处理和EBOV攻击期间在NHP中诱导的免疫应答是否足以保护存活者免受随后的暴露，在初始攻击后10或13周对在初始攻击中存活的动物进行再攻击。在10周时再激发的动物全部存活，而在13周时再激发的6只动物中有4只存活。数据表明，在用EBOV成功治疗EBOV感染的NHP期间产生了强有力的免疫应答，这导致针对第二次致死暴露的持续保护。
Ebola virus (EBOV) is one of the most lethal filoviruses, with mortality rates of up to 90% in humans. Previously, we demonstrated 100% and 50% survival of EBOV-infected cynomologus macaques with a combination of 3 EBOV-GP-specific monoclonal antibodies (ZMAb) administered at 24 or 48 hours post-exposure, respectively. The survivors demonstrated EBOV-GP-specific humoral and cell-mediated immune responses. In order to evaluate whether the immune response induced in NHPs during the ZMAb treatment and EBOV challenge is sufficient to protect survivors against a subsequent exposure, animals that survived the initial challenge were rechallenged at 10 or 13 weeks after the initial challenge. The animals rechallenged at 10 weeks all survived whereas 4 of 6 animals survived a rechallenge at 13 weeks. The data indicate that a robust immune response was generated during the successful treatment of EBOV-infected NHPs with EBOV, which resulted in sustained protection against a second lethal exposure.